DMYD-B:STO
Diamyd Medical AB
SEK 1.03
arrow_downward
-1.72%(-0.018) 1D
Okt 14, 5:21:24 PM GMT+2 · SEK
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa DMYD-B...
Buksan
SEK 1.05
Mataas
SEK 1.07
Mababa
SEK 1.01
Mkt. cap
155.73M
Avg. na dami
831.77K
Dami
172.28K
Mataas nang 52-wk
SEK 17.88
Mababa nang 52-wk
SEK 0.90
EPS
-SEK 1.76
Mga natitirang share
134.00M
Bilang ng mga empleyado
42
Buksan
SEK 1.05
Mataas
SEK 1.07
Mababa
SEK 1.01
Mkt. cap
155.73M
Avg. na dami
831.77K
Dami
172.28K
Mataas nang 52-wk
SEK 17.88
Mababa nang 52-wk
SEK 0.90
EPS
-SEK 1.76
Mga natitirang share
134.00M
Bilang ng mga empleyado
42
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
investingLive
·
4 oras ang nakalipas
S&P 500 decline extends to 100 points with tech hit particularly hard
investingLive
·
7 oras ang nakalipas
What technical levels are in play now for the broader US stock indices following the higher CPI data?
Yahoo Finance
·
1 linggo ang nakalipas
These 7 major S&P 500 stocks need to rally at least 200% to reclaim their peaks
The Guardian
·
1 linggo ang nakalipas
S&P 500 and Nasdaq surge to record highs after AI chipmaker rally
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
Tungkol sa Diamyd Medical AB